SciELO - Scientific Electronic Library Online

 
vol.73 número1Linfohistiocitosis hemofagocítica asociada con el virus de Epstein-Barr: respuesta al tratamiento con el protocolo HLH-04Infección en lactantes por virus de Epstein-Barr: implicaciones de la infección a temprana edad sobre el control viral y el riesgo de linfoma de Burkitt índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Boletín médico del Hospital Infantil de México

versión impresa ISSN 1665-1146

Resumen

AGUAYO-HIRALDO, Paibel; ARASARATNAM, Reuben  y  ROUCE, Rayne H.. Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease. Bol. Med. Hosp. Infant. Mex. [online]. 2016, vol.73, n.1, pp.31-40. ISSN 1665-1146.  http://dx.doi.org/10.1016/j.bmhimx.2015.11.007.

Fifty years after the first reports of Epstein-Barr virus (EBV)-associated endemic Burkitt's lymphoma, EBV has emerged as the third most prevalent oncogenic virus worldwide. EBV infection is associated with various malignancies including Hodgkin and non-Hodgkin lymphoma, NK/T-cell lymphoma and nasopharyngeal carcinoma. Despite the highly specific immunologic control in the immunocompetent host, EBV can cause severe complications in the immunocompromised host (namely, post-transplant lymphoproliferative disease). This is particularly a problem in patients with delayed immune reconstitution post-hematopoietic stem cell transplant or solid organ transplant. Despite advances in diagnostic techniques and treatment algorithms allowing earlier identification and treatment of patients at highest risk, mortality rates remain as high as 90% if not treated early. The cornerstones of treatment include reduction in immunosuppression and in vivo B cell depletion with an anti-CD20 monoclonal antibody. However, these treatment modalities are not always feasible due to graft rejection, emergence of graft vs. host disease, and toxicity. Newer treatment modalities include the use of adoptive T cell therapy, which has shown promising results in various EBV-related malignancies. In this article we will review recent advances in risk factors, diagnosis and management of EBV-associated malignancies, particularly post-transplant lymphoproliferative disease. We will also discuss new and innovative treatment options including adoptive T cell therapy as well as management of special situations such as chronic active EBV and EBV-associated hemophagocytic lymphohistiocytosis.

Palabras llave : Epstein-Barr virus; Post-transplant lymphoproliferative disease; Immunotherapy; Hematopoietic stem cell transplant; Solid organ transplant.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )